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Abstract
This study (NCT01288573) investigated plerixafor’s safety and efficacy in children with cancer. Stage 1 investigated the
dosage, pharmacokinetics (PK), pharmacodynamics (PD), and safety of plerixafor+ standard mobilization (G-CSF ±
chemotherapy). The stage 2 primary endpoint was successful mobilization (doubling of peripheral blood CD34+ cell count
in the 24 h prior to first apheresis) in patients treated with plerixafor+ standard mobilization vs. standard mobilization alone.
In stage 1, three patients per age group (2–<6, 6–<12, and 12–<18 years) were treated at each dose level (160, 240, and
320 µg/kg). Based on PK and PD data, the dose proposed for stage 2 was 240 µg/kg (patients 1–<18 years), in which
45 patients were enrolled (30 plerixafor arm, 15 standard arm). Patient demographics and characteristics were well balanced
across treatment arms. More patients in the plerixafor arm (24/30, 80%) met the primary endpoint of successful mobilization
than in the standard arm (4/14, 28.6%, p= 0.0019). Adverse events reported as related to study treatment were mild, and no
new safety concerns were identified. Plerixafor+ standard G-CSF ± chemotherapy mobilization was generally well tolerated
and efficacious when used to mobilize CD34+ cells in pediatric cancer patients.
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Introduction
Plerixafor (Mozobil®, Sanofi, Cambridge, MA, USA) is an
antagonist of the 7 transmembrane G protein coupled che-
mokine (C-X-C motif) receptor 4 (CXCR4) that works by
disrupting the interaction of CXCR4 with stromal cell-
derived factor-1, resulting in the release of CD34+ stem
cells into the circulation [1–4]. In the United States, pler-
ixafor is licensed for use in combination with granulocyte
colony stimulating factor (G-CSF) to mobilize hemato-
poietic stem cells (HSCs) into peripheral blood (PB) for
collection and subsequent autologous HSC transplantation
(HSCT) in adult patients with non-Hodgkin lymphoma or
multiple myeloma (MM). In the European Union, plerixafor
is indicated for use in combination with G-CSF to enhance
mobilization of HSCs into PB and subsequent autologous
HSCT in adults with lymphoma and MM, who are proven
to be poor mobilizers.
While the efficacy and safety of plerixafor is well
established in adults, limited data for its use in children are
available. This study investigated the appropriate dosing,
safety, and efficacy of plerixafor when given in combination
with G-CSF, in pediatric patients with different types of
cancer.
Methods
This was a phase I–II international, multicenter, randomized,
parallel assignment, open-label study of plerixafor in
pediatric cancer patients (ClinicalTrials.gov, NCT01288573;
EudraCT, 2010-019340-40). The study was conducted in
accordance with the Declaration of Helsinki and the Inter-
national Conference on Harmonization Guidelines for Good
Clinical Practice.
Independent ethics committees or institutional review
boards at the participating sites approved the protocol and
all amendments. All patients, and/or their legal guardians,
provided written informed consent prior to enrollment. The
study was conducted in two stages. Stage 1 (3+ 3 design)
investigated the appropriate dose, safety, pharmacokinetics
(PK) and pharmacodynamics (PD) of plerixafor in pediatric
cancer patients when given in addition to standard mobili-
zation (chemotherapy plus daily G-CSF or daily G-CSF
alone). Stage 2 was an open-label, comparative study to
evaluate the efficacy of plerixafor in addition to standard
mobilization regimens of HSCs into PB, and subsequent
collection by apheresis in pediatric patients with cancer
(Fig. 1).
Patients
Pediatric patients with Ewing’s sarcoma/soft tissue sar-
coma, neuroblastoma, brain tumors, and other malignancies
scheduled to undergo high-dose chemotherapy followed by
autologous HSCT were eligible for the study (Table 1). For
stage 1, patients were aged between 2 and <18 years, and in
stage 2, patients were aged 1–<18 years. Full exclusion
criteria are provided in the Supplementary Materials.
Study procedures
In stages 1 and 2, plerixafor was administered sub-
cutaneously at a separate anatomical site from the patient’s
standard mobilization treatment. All participating patients
received a standard mobilization regimen (chemotherapy
plus daily G-CSF or daily G-CSF alone) as per study site
practice guidelines. In stage 1, all patients received plerix-
afor in addition to the standard mobilization regimen. In
stage 2, 45 patients were randomized 2:1 to receive pler-
ixafor plus standard mobilization or standard mobilization
alone. In both stage 1 and stage 2, CD34+ cells were
obtained from venous blood samples by both local and
central laboratories for fluorescence-activated cell sorting
(FACS) analysis. CD34+ cell counts were obtained at
regular intervals to determine when the trigger point of
seven CD34+ cells/µL was reached, at which time plerix-
afor administration was scheduled for the next day.
In stage 1, three dose levels of plerixafor (160, 240, and
320 µg/kg) were studied for each of the age groups 2–<6
years, 6–<12 years, and 12–<18 years, respectively, (based
on the adult dose of 240 µg/kg). Blood samples were taken
to determine plerixafor concentrations in the plasma, which
were evaluated using liquid chromatography coupled with
Commence
Standard
mobilization 
Randomizationb
2:1 ratio
(Arm 1:Arm 2)
Apheresis
(max of
5 sessions)
30 day follow-up
or until day 1
of pre-transplant
myeloablative
therapy
HSCT(s)
(within 6 months
of last study
apheresis) 
24 months
post-transplant
follow-upc 
Arm 1: Plerixafor +
Standard mobilization
Arm 2: Standard
mobilization alone
Fig. 1 Stage 2 study design. a At least 40 patients were to be enrolled
into stage 2, which was open to patients with all malignant conditions
leading to autologous transplant except leukemia, but with the inten-
tion of acquiring a minimum of five patients for each of the following
diagnoses: Ewing’s sarcoma/soft tissue sarcoma, lymphoma,
neuroblastoma, and brain tumors. b Randomization based on day
when trigger point of ≥7 CD34+ cells/μL was reached. c Twenty-four
months after the last planned transplant performed within 6 months or
after last study apheresis if not transplanted.
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tandem mass spectrometry with a lower limit of quantifi-
cation of 5 ng/mL. Venous blood samples were collected for
CD34+ FACS analysis on the morning of the day preced-
ing the first apheresis and on the morning of the apheresis
day (prior to administration of the daily G-CSF dose). For
each apheresis collection, apheresis product volume, abso-
lute number of CD34+ cells per unit volume, and the
patient’s weight were used to calculate the yield of CD34+
cells/kg. The total CD34+ cell yield was calculated as the
sum of all apheresis collections.
In stage 2, all patients received standard mobilization
with G-CSF, dosed at 10 µg/kg daily. In patients mobilizing
poorly prior to randomization, the dose of G-CSF could be
increased up to a maximum of 15 µg/kg (three (10%)
patients in the plerixafor arm and one patient in the standard
(6.6%) therapy arm) if this was in accordance with the study
site standard practice. Patients were randomized when the
trigger point of seven CD34+ cells/µL was reached (a
threshold of seven CD34+ cells/µl was chosen as the lowest
threshold to maximize the probability that patients could
achieve apheresis following randomization).
Plerixafor was dosed at 240 µg/kg (determined in stage
1) between 8 and 12 h before the planned apheresis as
CD34+ cell counts peak ~9 h after plerixafor mobilization.
A maximum of five apheresis sessions were permitted for
each patient. On the morning of the day preceding the first
apheresis and on the morning of the apheresis day itself
(prior to administration of the daily G-CSF), venous blood
samples were taken for PB CD34+ FACS analysis.
The primary stage 2 efficacy endpoint was successful
mobilization, defined as at least a doubling of PB CD34+
cell count in the 24 h prior to first apheresis. Secondary
stage 2 endpoints included safety, number of days of
apheresis required to reach ≥2 × 106 CD34+ cells/kg,
CD34+ yield per apheresis, total CD34+ cell yield, and
percentage of patients proceeding to transplant, successfully
engrafting, and the number of patients with durable
engraftment at 3, 6, 12, and 24 months post transplant.
Exploratory endpoints included the CD34+ cell count
that was transplanted, increase in CD34+ cell counts, total
blood volume processed, time to neutrophil engraftment,
and time to platelet engraftment.
Treatment-emergent adverse events (TEAEs) were
defined as any adverse event from the date of randomization
until 30 days after the last dose of the patient’s study
mobilization regimen, or until the first dose of their next
anticancer therapy or pretransplant myeloablative therapy,
whichever occurred first. Safety was assessed in stage 1 and
stage 2 by monitoring TEAEs. All patients who underwent
transplant within 6 months of their last study apheresis were
evaluated up to 24 months after their last transplant. For
patients who did not undergo transplant, safety was mon-
itored up to 24 months after the last dose of study mobili-
zation treatment.
Statistical assessments
A standard 3+ 3 dose parallel escalation strategy was used
to determine dose per age cohort in stage 1. For each
planned plerixafor dose (160, 240, and 320 µg/kg), 9
patients (3 per age group [2–<6 years, 6–<12 years, and
12–<18 years]) were to be included for a total of 27
patients. Further three patients would be enrolled in a cohort
if a dose limiting toxicity occurred. Escalation would only
occur if <2 patients exhibited unacceptable toxicities.
For stage 2, it was planned to enroll 40 patients; 27
patients in the plerixafor arm and 13 in the standard arm
(2:1 ratio). The sample size has been determined by the
ability to recruit patients to the study, based on known
numbers of autologous transplants carried out in pediatric
cancer patients, diagnoses to be included in this study, and
limiting participation to larger sites that have capability to
achieve sufficient patient numbers within a reasonable
amount of time. No formal statistics-based on sample size
calculations have been performed.
The full analysis set comprised all patients randomized in
stage 2. Patients were analyzed according to the treatment
arm allocated by randomization (intention-to-treat analysis).
Continuous variables were summarized using either mean
Table 1 Stage 1 patient baseline characteristics.
Age 2–<6
years
(n= 9)
Age 6–<12
years
(n= 9)
Age 12–<18
years
(n= 9)
Age [years], mean ± SD 3.1 ± (1.2) 8.8 ± 1.7 15.3 ± 1.1
Male, n (%) 2 (22) 7 (78) 3 (33)
Race, n (%)
White 8 (89) 9 (100) 8 (89)
Asian 1 (11) 0 1(11)
Ethnicity, n (%)
Hispanic or Latino 0 0 0
Not Hispanic or Latino 7 (78) 9 (100) 8 (89)
Not reported 2 (22) 0 1 (11)
Tumor type, n (%)
Ewing’s sarcoma 0 3 (33) 3 (33)
Hodgkin’s lymphoma 0 0 3 (33)
Medulloblastoma 0 0 0
Neuroblastoma 7 (78) 4 (44) 2 (22)
Non-Hodgkin’s
lymphoma
0 1 (11) 0
Rhabdomyosarcoma 1 (11) 0 1 (11)
PNET 1 (11) 0 0
CNS tumor not
germinomatous
0 1 (11) 0
Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric. . .
and standard deviation (SD), or median and range (mini-
mum to maximum). Categorical and ordinal data were
summarized using the number and percentage of patients in
each treatment arm. All summaries and statistical analyses
were generated using SAS software version 9.0 or higher.
Test for statistical significance was performed only on the
primary efficacy endpoint.
Results
Stage 1
Twenty-seven patients were included in three age groups
(2–<6, 6–<12, and 12–<18 years) with three patients in
each age group treated at each dose level (160, 240, and
320 µg/kg) (Table 1).
Pharmacokinetic parameters are summarized in Table 2.
There was considerable variability in PK parameters within
each age cohort due to low numbers of patients. As the dose
of plerixafor was raised from 160 to 240 µg/kg, exposure (as
assessed by Cmax) to plerixafor generally increased in all age
cohorts; further increases between 240 and 320 µg/kg were
observed in the youngest and oldest age cohorts. Mean
AUC0–9 h values did not appear to increase between the
240 µg/kg and 320 µg/kg doses in the youngest and middle
age groups, but were proportional between the 160 µg/kg
and 320 µg/kg doses in the oldest group. There was a trend
toward lower exposures in the youngest age categories;
however, the trend was not clinically relevant, and exposure
was sufficient for a response. In general, at all dose levels,
CD34+ cells counts within the first hour after dosing lag
behind the maximum plasma concentrations of plerixafor,
although there was variation between individual patients
(Supplementary Fig. 1a, b). The delayed increase in CD34+
cell count with rising plerixafor concentration is consistent
with the PK/PD relationship observed in adults. In addition,
the PD response regarding CD34+ cell count was com-
parable across all dose levels. Therefore, the dose proposed
for stage 2 was 240 µg/kg to be given between 8 and 12 h
before apheresis. Overall, three patients failed to reach 2 ×
106 cells/kg (one patient in the 2–<6 years cohort and two in
the 12–18 years cohort (Table 3).
No dose limiting toxicities were observed in stage 1.
TEAEs were experienced by 16 patients (59%); 9 patients
(33%) experienced a serious TEAE. All serious TEAEs
were attributed to the effects of mobilizing chemotherapy
and not related to study treatment. Four deaths occurred
after the 30-day period following the last plerixafor dose;
three due to disease progression (none of these patients
received HSCT) and one patient through a cerebral
hemorrhage, of which treatment with heparin was likely
the cause. Ta
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Stage 2
Forty-five patients were enrolled in stage 2 (30 plerixafor
arm, 15 standard arm); 35 patients completed all study
follow-up visits. Patient demographics and characteristics
were well balanced across patient cohorts with little varia-
tion in diagnosis of underlying disease between age groups
(Table 4). Baseline PB CD34+ cell count (last value
recorded prior to randomization) was numerically higher in
the standard arm than for the plerixafor arm (27.0 vs.
14.8 cells/μL, respectively; no statistical analysis was car-
ried out on baseline parameters). More patients in the
plerixafor arm had PB CD34+ cell counts of <20 cells/µL
on the day before first apheresis than in the standard arm
(Table 5). Ten patients discontinued the study (Table 6).
Efficacy
More patients in the plerixafor arm (24/30, 80%) met the
primary endpoint of doubling the PB CD34+ cell count in the
24 h prior to first apheresis than in the standard arm (4/14,
28.6%) (p= 0.0019; Table 6). Three patients in the plerixafor
arm and one patient in the standard arm failed to reach 2 × 106
CD34+ cells/kg (Table 6). The median total CD34+ cell
yield was numerically higher in the standard arm (Table 6).
During the 6-month time period following mobilization
23/30 (76.7%) patients in the plerixafor arm and 10/15
(66.7%) patients in the standard arm proceeded to HSCT.
All patients who received HSCT had successful engraft-
ments. The median number of CD34+ cells infused at
transplant was 4.55 × 106 cells/kg in the standard arm and
4.16 × 106 cells/kg in the plerixafor arm (Table 6). Rates of
neutrophil, platelet, and sustained engraftment were com-
parable between treatment arms (Table 6).
On the day prior to the first planned apheresis median PB
CD34+ cell counts were lower in the plerixafor arm than
in the standard arm; by the day of apheresis median PB
CD34+ cell counts were higher in the plerixafor arm than in
the standard arm (Table 6). An ad hoc analysis demon-
strated that patients in the plerixafor arm (n= 27) experi-
enced a median PB CD34+ cell increase of 3.2-fold in the
24 h prior to first apheresis compared with a 1.39-fold
increase for patients in the standard arm (n= 14).
Stage 2 safety results
In the plerixafor arm 76.7% of patients experienced a TEAE
compared with 66.7% of patients in the standard arm
(Table 7). The number of TEAEs grade 3 or higher were
comparable between arms (43.3% plerixafor arm vs. 40.0%
standard arm) (Table 7). No TEAEs grade 3 or higher or
SAEs related to study treatment were observed. TEAEs
assessed as related to the study treatment were reported forTa
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four patients (13.3%) in the plerixafor arm and no patients
in the standard arm: injection site reactions (6.7%), hypo-
kalemia (3.3%), blood bicarbonate increased (3.3%). No
patient discontinued study treatment due to a TEAE or
experienced a TEAE leading to death. The number of
patients with myeloablative conditioning before transplan-
tation are shown in Table 8 (stage 1 and stage 2). Six
patients (three in each study arm) died during the study; all
deaths were due to disease progression and occurred during
the posttreatment follow-up period.
Discussion
This study is the first to address the dose and timing of
plerixafor in pediatric patients with cancer and allowed for
efficacy and safety to be assessed in this patient population.
Stage 1 of this study was conducted to establish the PK
of plerixafor in the pediatric population. No apparent dose-
dependent effect of plerixafor on CD34+ cumulative cell
yield or fold increases were observed observed and efficacy
and safety of plerixafor in this study was similar to that
observed in adults at all three doses explored. Therefore the
recommended adult dose of 240 µg/kg, administered 8–12 h
prior to apheresis, was recommended in pediatric patients.
The primary endpoint, defined as at least a doubling of
PB CD34+ cell count in the 24 h prior to first apheresis
(i.e., prior to first administration of plerixafor in the
experimental arm), was significantly higher in the plerixafor
arm than in the standard arm (p= 0.0019). The primary
endpoint allowed for the measure of the role of plerixafor in
addition to standard mobilization with G-CSF alone or in
combination with chemotherapy in order to not modify the
standard mobilization regimens currently used. Of note, on
the day prior to the first planned apheresis, CD34+ cell
counts were more than twofold higher in patients rando-
mized to the standard arm than in the plerixafor arm. The
added value of plerixafor treatment can be seen in the
increase in CD34+ cell counts on day 1 of apheresis
from the day prior to apheresis, with patients in the pler-
ixafor arm experiencing a greater median fold change (3.2-
fold vs. 1.39-fold) in CD34+ cell counts than those in the
standard arm.
Table 4 Stage 2 patient baseline characteristics.
Age group 1–<6 years Age group 6–<12 years Age group 12–<18 years
Standard arm
(n= 10)
Plerixafor
arm (n= 16)
Standard
arm (n= 3)
Plerixafor
arm (n= 9)
Standard
arm (n= 2)
Plerixafor
arm (n= 5)
Age [years], mean ± SD 3.2 ± 1.3 3.6 ± 1.2 6.7 ± 0.8 8.0 ± 1.6 14.3 ± 2.7 15.8 ± 1.5
Male, n (%) 4 (40) 9 (56) 2 (67) 6 (67) 1 (50) 4 (80)
Race, n (%)
Caucasian 9 (90) 16 (100) 3 (100) 8 (89) 2 (100) 5 (100)
Not reported 1 (10) 0 0 1 (11) 0 0
Ethnicity, n (%)
Hispanic or Latino 1 (10) 1 (6) 0 1 (11) 0 2 (40)
Not Hispanic or Latino 8 (80) 15 (94) 3 (100) 7 (78) 2 (100) 3 (60)
Not reported 1 (10) 0 0 1 (11) 0 0
Tumor type, n (%)
Lymphoma 1 (10) 0 0 0 0 2 (40)
Neuroblastoma 6 (60) 12 (75) 1 (33) 2 (22) 0 0
Sarcoma 0 0 2 (67) 6 (67) 2 (100) 2 (40)
Medulloblastoma 1 (10) 2 (13) 0 1 (11) 0 0
Wilms’ tumor 1 (10) 1 (6) 0 0 0 0
Anaplastic ependymoma 1 (10) 0 0 0 0 0
Malignant rhaboid tumor 0 1 (6) 0 0 0 0
Intracranial germ cell tumor 0 0 0 0 0 1 (20)
Patient percentages are a proportion of the treatment arm for all age groups combined (standard mobilization group or plerixafor+ standard
mobilization group).
Table 5 Number (%) of patients with PB CD34+ cell count (cells/µL)
less than 10, 15, or 20 on the day before first apheresis.
Standard arm (N= 15) Plerixafor arm (N= 30)
Central laboratory measurement, n (%)
<10 cells/µL 3 (20) 4 (13.3)
<15 cells/µL 4 (26.7) 14 (46.7)
<20 cells/µL 4 (26.7) 17 (56.7)
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Table 6 Summary of stage 2 efficacy endpointsa.
Primary endpoint Standard arm (N= 15) Plerixafor arm (N= 30)
Primary analysis
Successful mobilizationb, n/N1(%), [95% CI] 4/14 (28.6)
[8.4%, 58.1%]
24/30 (80.0)
[61.4%, 92.3%]
Difference of proportion of successful mobilizationc 51.4
95% CL [18.5%, 84.3%]
p valued 0.0019
Secondary and exploratory endpoints Standard arm (N= 15) Plerixafor arm (N= 30)
Number of days required to reach ≥2 × 106 cells/kg, median [95% CI] 1 [NC, NC] 1 [NC, NC]
Cumulative patients reaching ≥2 × 106 cells/kg, n (%)a
Day 1 15 (100) 26 (89.7)
Day 2 15 (100) 27 (94.4)
Day 3 15 (100) 27 (94.4)
Day 4 15 (100) 27 (94.4)
Day 5 15 (100) 27 (94.4)
Patients not reaching target of ≥2 × 106 cells/kg by apheresis day 5, n (%) 1 (7.1) 3 (10.3)
Total blood volume processed [L], median 3.27 3.00
Cumulative CD34+ cell collection (106 cells/kg)e
Number 14 29
Median 10.2 9.1
Min:Max 0.7:66.0 0.1:200.4
Number of patients who received transplants 10 (66.7) 23 (76.7)
Number of CD34+ cells (106 cells/kg) infused on transplant day, median (min:max) 4.55 (0.5:9.4) 4.16 (0.1:12.0)
Percentage of durable engraftment after transplant, n/n (%), [95% CI]f
Month 3 10/10 (100) [69.2, 100.0] 21/23 (91.3) [72.0, 98.9]
Month 6 9/10 (90.0) [55.5, 99.7] 20/23 (87.0) [64.4, 97.2]
Month 12 8/10 (80.0) [44.4, 97.5] 20/23 (87.0) [64.4, 97.2]
Month 24 8/10 (80.0) [44.4, 97.5] 19/23 (82.6) [61.2, 95.0]
Time to neutrophil engraftment [days], Median (95% CI)g 14 (11.0%, 15.0%) 12 (11.0%, 13.0%)
Time to platelet engraftment [days], Median (95% CI)g 23 (11.0%, 31.0%) 28 (18.0%, 37.0%)
Peripheral Blood CD34+ cell count (cells/μL) summary, median (min:max)
Day prior to first planned apheresis 35.0 (5.0:300.00) 15.0 (1.0:306.0)
Day 1 first planned apheresis 64.0 (11.00:510.00) 77 (0.0:959.0)
Day 1 increase in CD34+ counts from day prior 12 (−17.0:362.0) 53.0 (−45.0:653.0)
Reason for study discontinuation, n (%) Standard arm
(N= 15)
Plerixafor arm
(N= 30)
Progressive disease 1 (6.7) 0
Deathh 3 (20.0) 3 (10.0)
Investigator’s choicei 0 1 (3.3)
Subject/parent request 1 (6.7) 1 (3.3)
CI confidence interval, n number of patients who successfully mobilized, N1 number of patients excluding patients missing both local and central
laboratory records, NC not calculated.
aData for the primary analysis is from the central laboratory. In case of missing data from the central laboratory, the corresponding local laboratory
result was used for primary analysis.
bThe primary endpoint of successful mobilization is defined as at least a doubling of the peripheral blood (PB) CD34+ count from the morning of
the day preceding the first planned apheresis day to the morning prior to apheresis. The 95% CIs are calculated using the exact method.
cThe difference in the proportion of patients who met the primary endpoint is calculated relative to standard mobilization alone treatment arm. The
CI of the difference is based on the Wald asymptotic CI with continuity correction method.
dThe p value is based on the Fisher’s exact test comparing the proportion of successful mobilization between the two treatment arms.
eData from central laboratory.
fCI is estimated using exact method. Percentages are based on N1.
gCL estimated by Kaplan–Meier method using log–log transformation.
hDeath due to progressive disease.
iInvestigator felt the patient needed more mobilization after first apheresis.
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In adults, plerixafor has been observed to be advanta-
geous in patients considered to be poor mobilizers using the
current consensus threshold for poor mobilization in adults
(<20 CD34+ cells/µL) [5–7]. However, the adult “con-
sensus” threshold for poor mobilization may not be appro-
priate in the pediatric setting [8]. Few studies have been
published exploring poor mobilization in pediatric patients
and therefore there is no current consensus threshold
for poor mobilization in this patient group. In a single ret-
rospective study of pediatric patients, who received a
mobilization regime consisting of G-CSF for 4 days, prior
to collection of CD34+ cells, [8] no differences were
observed in the numbers of patients reaching the target cell
dose (2 × 106 cells/µL) for autologous PB progenitor cell
transplantation in patients with baseline PB CD34+ cells
counts of >20 cells/µL compared with those with baseline
CD34+ cells counts of 11–20 cells/µL [8]. Of 26 pediatric
patients with a PB CD34+ cell count of ≤10 cell/µL, 18
underwent hematopoietic progenitor cell collection, two
reached the target CD34+ cell dose after one apheresis, and
16 failed to reach the target [8].
Data for use of plerixafor for mobilization of HSC in
pediatric patients are sparse. Studies, with limited numbers
of pediatric patients who had failed earlier mobilization
with chemotherapy and G-CSF, or G-CSF alone, have
demonstrated that plerixafor combined with G-CSF can
result in successful mobilization [9–12]. In a more com-
prehensive study of 33 pediatric patients who had pre-
viously failed to mobilize using G-CSF mobilization
regimes, 31 patients successfully mobilized CD34+ cells
after treatment with plerixafor, with 27 patients meeting the
target of 2 × 106 cell/kg after one apheresis procedure and
24 patients proceeded to transplant [13].
In the current study, more patients in the plerixafor arm
than in the standard arm successfully mobilized cells it is
important to note that both arms had high levels of suc-
cessful mobilization, suggesting plerixafor may have a
specific role in the population of patients who are poor
mobilizers [14]. Again, it was noted that the plerixafor arm
had a higher proportion of potential poor mobilizers (as
defined using the current consensus threshold for poor
mobilization in adults, <20 CD34+ cells/µL), than in the
standard arm. The higher number of poor mobilizers in the
plerixafor group may have contributed to a trend in slower
platelet engraftment observed in the plerixafor group,
median time to engraftment 28 days in the plerixafor arm
compared with 23 days in the standard arm. However, in
another study in children with malignant tumors, the median
time to platelet engraftment with plerixafor was 16 days
(range 9–30 days) [13], which is similar to the median time
of 18–21 days for platelet engraftment observed for both
plerixafor plus G-CSF and the G-CSF alone arms in adult
Table 7 Overview of treatment-emergent adverse events during
stage 2.
Parameter, n (%) Standard arm
(N= 15)
Plerixafor arm
(N= 30)
Any TEAE 10 (66.7) 23 (76.7)
TEAE related to study procedure 4 (26.7) 12 (40.0)
TEAE related to study treatmenta 0 4 (13.3)
Injection site reactions 2 (6.7)
Hypokalemia 1 (3.3)
Blood bicarbonate increased 1 (3.3)
Any grade 3–4 TEAE 6 (40.0) 13 (43.3)
Any grade 3–4 TEAE related to
study procedure
4 (26.7) 9 (30)
Any grade 3–4 TEAE related to
study treatment
0 0
Any serious TEAE 4 (26.7) 9 (30)
Serious TEAE related to study
procedure
1 (6.7) 3 (10)
Serious TEAE related to study
treatment
0 0
TEAE treatment-emergent adverse event.
aAll were common terminology criteria for adverse events grade 1.
Table 8 Patients with myeloablative conditioning before transplantation (a) stage 1 and (b) stage 2.
(a) Stage 1
Age 2–<6 years
(n= 9)
Age 6–<12 years
(n= 9)
Age 12–<18 years
(n= 9)
Patients, n (%) 8 (88.9) 6 (66.7) 5 (55.6)
(b) Stage 2
Age group 1–<6 years Age group 6–<12 years Age group 12–<18 years
Standard arm
(n= 10)
Plerixafor arm
(n= 16)
Standard arm
(n= 3)
Plerixafor arm
(n= 9)
Standard arm
(n= 2)
Plerixafor arm
(n= 5)
Patients, n (%) 7 (70) 13 (81) 2 (67) 8 (89) 1 (50) 3 (60)
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patients with non-Hodgkin’s lymphoma and MM [15, 16].
It is known that there are differences in the cellular com-
position of apheresis products recovered from healthy adults
who received either plerixafor plus G-CSF or G-CSF alone
[17]. Nevertheless, there is no evidence from studies in
adult lymphoma or MM patients that potential differences in
apheresis product affects platelet engraftment [15, 16]. The
results of the previous pediatric published literature, in
which high levels of successful mobilization were observed
in patients that had previously failed to mobilize on alter-
native mobilization regimes, provide further support for the
use of plerixafor in HSC mobilization [9–13].
Adverse events reported as related to study treatment in
the current study were mild and consistent with the known
safety profile of plerixafor. In addition, few AEs have been
reported in other studies investigating the use of plerixafor
in pediatric patients [9, 11, 12]. Maschan et al. [13] noted
mild toxicity in 8 out of 33 patients including World Health
Organization grade 1/2 diarrhea (n= 5), grade 2 nausea
(n= 2), grade 1 bone pain (n= 1), and urticaria (n= 1).
Hong et al. reported that two patients with medulloblastoma
developed pneumomediastinum, with pathogenic findings
consistent with diffuse alveolar damage [10].
In summary, this study has established the dose and
timing of plerixafor in pediatric patients as 240 µg/kg to
be administered between 6 and 11 h before apheresis.
More patients in the plerixafor arm, than in the standard
arm, met the primary endpoint of successful mobilization
supporting the role of plerixafor on increasing the number
of mobilized CD34+ cells in PB, especially in poor
mobilizers. Adverse events reported as related to study
treatment were mild, and no new safety concerns were
identified in this study. Overall, plerixafor was generally
well tolerated and efficacious when used to mobilize
CD34+ cells in pediatric patients with a variety of dif-
ferent cancers.
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